Whitehawk Therapeutics WHWK 深 沪
已收盘 05-22 16:00:00 美东时间
4.49
+0.190
+4.42%
华盛通- 最 高4.70
- 今 开4.45
- 成交量 34.71万股
- 最 低 4.38
- 昨 收 4.30
- 总市值 2.22亿
- 52周最高 5.495
- 市盈率 静 --
- 换手率 0.70%
- 52周最低 1.57
- 委 比 -65.52%
- 总股本 4945.25万
- 历史最高 65.25
- 量 比 1.56
- 振 幅 7.44%
- 历史最低 1.21
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Whitehawk Therapeutics Enters Into A New Option Agreement With Hangzhou DAC For Access To CPT113 For Use In Up To Five Additional ADC Programs; Phase 1 Dose-Escalation Trials Of HWK-007 And HWK-016 Are Currently Enrolling; HWK-007 Trials-In-Progress Poster To Be Presented At ASCO
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate
05-22 05:11
美股牛股 | 3D打印公司VELO单日劲升超49%！Q1业绩大超预期；新股FRVO首日涨超35%
3D打印公司VELO单日劲升超49%！Q1业绩大超预期；新股FRVO首日涨超35%，受益于AI用电需求爆发；激光雷达公司OUST涨超26%，旗下产品获英伟达认证>>
05-14 19:36
Whitehawk Therapeutics secures $87.5M PIPE financing
Whitehawk Therapeutics (WHWK) announced on Wednesday that it has entered into a securities purchase agreement for an $87.5M private investment in public equity, or PIPE, financing, before deducting pl...
05-13 20:47
Whitehawk Therapeutics Enters PIPE Financing With Expected Gross Proceeds Of ~$87.5M From Sale Of 4,330,866 Shares At $3.92 Per Share And Warrants To Purchase 17,991,021 Shares At $3.9199 Per Warrant
Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (NASDAQ:WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved
05-13 20:12
Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing
MORRISTOWN, N.J., May 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (the "Company" or "Whitehawk") (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced te...
05-13 20:00
Whitehawk Therapeutics Q1 EPS $(0.32) Misses $(0.09) Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.09) by 255.56 percent. This is a 117.49 percent decrease over earnings of $1.83 per
05-07 20:22
Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK)
In a report released today, Jeff Jones from Oppenheimer reiterated a Buy rating...
04-21 20:17
Reported Sunday, Whitehawk Therapeutics Presents Preclinical Data For HWK-007, HWK-016 And HWK-206 Next-Generation ADC Portfolio At AACR 2026, Showing Tumor Regressions At Low Single-Digit Mg/Kg Doses
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platformTumor regressions observed across various cancer models at
04-20 16:29
Whitehawk Therapeutics publishes HWK-016 preclinical presentation on MUC16-targeting ADC
Whitehawk Therapeutics publishes HWK-016 preclinical presentation on MUC16-targeting ADC Whitehawk Therapeutics published preclinical data for HWK-016, a MUC16-targeting antibody-drug conjugate designed to bind non-shed MUC16 extracellular domain rather than circulating CA125. In cell assays, exogen
04-20 11:45
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
